Search This Blog

Wednesday, September 2, 2026

Vertex sees >$5B peak annual revenue from PALSONIFY, atumelnant with Crinetics acquisition

 

Vertex sees >$5B peak annual revenue from PALSONIFY, atumelnant after completing ~$10B acquisition of Crinetics

  • Vertex guides the Crinetics acquisition will be accretive to non-GAAP operating income in 2029.
  • Acquisition adds PALSONIFY and atumelnant endocrine portfolio from Crinetics to Vertex's pipeline.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)